Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
- Details
- Category: Novartis
Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) were published in the peer-reviewed journal The Lancet. These pivotal results show significant reductions in the risk of three- (primary endpoint) and six-month confirmed disability progression with siponimod versus placebo[1] and favorable outcomes in other relevant measures of MS disease activity[1].
Lokelma approved in the EU for the treatment of adults with hyperkalaemia
- Details
- Category: AstraZeneca
AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.(1,2,3,4)
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
- Details
- Category: Novartis
Novartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies.
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA's Fast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need in an effort to get treatments to those in need sooner.
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay EUR 100 million (approximately DKK 750 million) upfront and is furthermore required to later pay up to EUR 805 million (approximately DKK 6 billion) in development and sales milestones to the group of current owners.
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
- Details
- Category: AstraZeneca
AstraZeneca has announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines.
Novartis announces changes to the Executive Committee to support strategic priorities
- Details
- Category: Novartis
Novartis announced today changes to its senior leadership team to support the implementation of its strategic priorities. Bertrand Bodson, Chief Digital Officer, Steffen Lang, Global Head Novartis Technical Operations, and Shannon Klinger, Chief Ethics, Risk and Compliance Officer, have been appointed to the Executive Committee of Novartis (ECN).
More Pharma News ...
- Novartis expands alliance with Science 37 to advance virtual clinical trials program
- Bristol-Myers Squibb's Opdivo® (nivolumab) now the first and only FDA-approved PD-1 inhibitor to offer every four-week dosing
- Novartis' Xolair® recommended in new global chronic urticaria guideline
- FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
- Bristol-Myers Squibb announces expansion of the International Immuno-Oncology Network (II-ON) with addition of Yale Cancer Center
- Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
- MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics